Company: INDP
Filing Date: 2025-04-17
Form Type: PRE 14A
Source: 0001641172-25-005234
Chunk: 35

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-04-17
Form: PRE 14A
Chunk 35
---
 |

<div align='center'>REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS</div>

The Audit Committee has reviewed the audited consolidated financial statements of Indaptus Therapeutics, Inc. (the “Company”) for the fiscal year ended December 31, 2024 and has discussed these financial statements with management and the Company’s independent registered public accounting firm. The Audit Committee has also received from, and discussed with, the Company’s independent registered public accounting firm various communications that such independent registered public accounting firm is required to provide to the Audit Committee, including the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board (“PCAOB”) and the SEC.

The Company’s independent registered public accounting firm also provided the Audit Committee with a formal written statement required by PCAOB Rule 3526 ( Communications with Audit Committees Concerning Independence) describing all relationships between the independent registered public accounting firm and the Company, including the disclosures required by the applicable requirements of the PCAOB regarding the independent registered public accounting firm’s communications with the Audit Committee concerning independence. In addition, the Audit Committee discussed with the independent registered public accounting firm its independence from the Company.

Based on its discussions with management and the independent registered public accounting firm, and its review of the representations and information provided by management and the independent registered public accounting firm, the Audit Committee recommended to the Board of Directors that the audited consolidated financial statements be included in the 2024 Annual Report.

William B. Hayes (Chairman)

Hila Karah

Robert E. Martell, M.D., Ph.D.

<div align='center'>EXECUTIVE OFFICERS</div>

The following table identifies our current executive officers:

| Name                  |     | Age |     | Position                        |
| Jeffrey               
 A. Meckler (1)        |     |  58 |     | Chief                           
 Executive Officer and Director  |
| Michael               
 J. Newman, Ph.D. (2)  |     |  69 |     | Chief                           
 Scientific Officer and Director |
| Nir                   
 Sassi (3)             |     |  49 |     | Chief                           
 Financial Officer               |
| Walt                  
 A. Linscott, Esq. (4) |     |  65 |     | Chief                           
 Operating Officer               |
| Roger                 
 J. Waltzman, M.D. (5) |     |  58 |     | Chief                           
 Medical Officer                 |

| (1) | See                                                                                                                                              
 biography on page